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Creation of haemoglobin A1c direct 
oxidase from fructosyl peptide 
oxidase by combined structure-
based site specific mutagenesis and 
random mutagenesis
Noriyuki ogawa1, Takehide Kimura1, Fumi Umehara1, Yuki Katayama1, Go Nagai1, 
Keiko Suzuki2, Kazuo Aisaka2, Yukie Maruyama3,4, Takafumi Itoh3,5, Wataru Hashimoto3, 
Kousaku Murata3,4 & Michio Ichimura1
The currently available haemoglobin A1c (HbA1c) enzymatic assay consists of two specific steps: 
proteolysis of HbA1c and oxidation of the liberated fructosyl peptide by fructosyl peptide oxidase 
(FPOX). To develop a more convenient and high throughput assay, we devised novel protease-free 
assay system employing modified FPOX with HbA1c oxidation activity, namely HbA1c direct oxidase 
(HbA1cOX). AnFPOX-15, a modified FPOX from Aspergillus nidulans, was selected for conversion to 
HbA1cOX. As deduced from the crystal structure of AnFPOX-15, R61 was expected to obstruct the 
entrance of bulky substrates. An R61G mutant was thus constructed to open the gate at the active site. 
The prepared mutant exhibited significant reactivity for fructosyl hexapeptide (F-6P, N-terminal amino 
acids of HbA1c), and its crystal structure revealed a wider gate observed for AnFPOX-15. To improve 
the reactivity for F-6P, several mutagenesis approaches were performed. The ultimately generated 
AnFPOX-47 exhibited the highest F-6P reactivity and possessed HbA1c oxidation activity. HbA1c levels 
in blood samples as measured using the direct assay system using AnFPOX-47 were highly correlated 
with the levels measured using the conventional HPLC method. In this study, FPOX was successfully 
converted to HbA1cOX, which could represent a novel in vitro diagnostic modality for diabetes mellitus.
Haemoglobin A1c (HbA1c) is a species of glycated haemoglobin (Hb) that is generated by non-enzymatic con-
densation between the amino group of the N-terminal valine of the Hb β-chain and glucose in the red blood 
cells1. This in vitro diagnostic modality can serve as a biomarker for diabetes mellitus. HbA1c reflects the blood 
glucose level over the last 2–3 months2, and it is calculated as the percentage of abundance of HbA1c relative 
to the total Hb concentration. Currently, HbA1c is measured using several assay methods, such as HPLC3, the 
LATEX immunoturbidimetric assay4 and enzymatic assay5. The recently developed HbA1c enzymatic assay has 
become particularly popular because of easy handling on conventional autoanalysers and cost-effectiveness in 
comparison to other assay methods.
The current HbA1c enzymatic assay consists of two specific enzymatic reactions: i) HbA1c is degenerated 
by detergents and proteolysed to generate the fructosyl dipeptide fragment, fructosyl valyl histidine (F-VH). 
“Fructosyl” indicates the attachment of a 1-deoxy-fructosyl moiety to the amino group of the amino acid via 
glycation. ii) The liberated F-VH reacts with FPOX to generate glucosone, valyl histidine (VH) and hydrogen 
peroxide (H2O2). Afterwards, according to the general detection method, the generated H2O2 is then reacted with 
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a chromogen in the presence of peroxidase to produce a dye. The concentration of F-VH can be quantitatively 
determined by measuring the specific absorption of the dye. The amount of F-VH reflects that of HbA1c stoichi-
ometrically (Fig. 1(a)).
A number of enzymes, termed fructosyl amino acid oxidase (FAOX), have reactivity for fructosyl amino acids 
as major substrates6. Some of these enzymes, which also exhibit reactivity for fructosyl dipeptides as F-VH are 
specifically termed fructosyl peptide oxidase (FPOX). Because of their reactivity for F-VH, current HbA1c enzy-
matic assays often employ FPOX for a more specific measurement of HbA1c6. In this report, we termed these 
fructosyl substrate reactive enzymes FPOX generically.
To meet the rapidly growing demand for more convenient monitoring of diabetes mellitus, we devised to 
develop protease-free enzymatic HbA1c in vitro diagnostics, namely “HbA1c direct enzymatic assay”. This new 
assay is expected to bring several benefits. In particular, i) excluding the proteolysis step directly contributes to the 
convenience of measurement, which could also reduce reagent costs. Second, ii) skipping the proteolysis step also 
opens the possibility of shortening measuring time, which is advantageous for high throughput measurement. 
To construct such a novel system, we took the strategy to modify FPOX with direct oxidation activity for a whole 
HbA1c protein.
To date, structurally modified FPOX with improved specificity for HbA1c-derived fragments, such as 
α-fructosyl valine (F-V) or F-VH, and lower reactivity for ε-fructosyl lysine (ε-F-K), have been developed via 
several mutagenesis approaches7–11. With respect to current assay system, the combination of a modified specific 
FPOX and adequate protease selection at the first step realises substantially specific measurement of HbA1c.
On the other hand, the idea for creating HbA1cOX via FPOX modification and application to a novel enzy-
matic assay is referred in some reports6,12–15. Some wild-type or modified FPOX have been reported to have 
oxidation activities for fructosyl hexapeptide (F-6P, Fru-VHLTPE) of the N-terminal amino acids of HbA1c16 
(Fig. 1(b)). The other modified FPOX were reported to exhibit reactivity for bulky substrates such as fructosyl 
poly-lysine or fructosyl adamantanamine12,13. Despite such active modification studies, no modified FPOX was 
reported to demonstrate the oxidation activity towards whole glycated proteins, including HbA1c.
We sought to create HbA1cOX by modifying fungal FPOX. First, we tried to isolate template FPOX for mod-
ification from a fungal library based on substrate specificity (Supplementary Information). Previous research 
proposed that fungal FPOX enzymes could be divided into three groups (group I-III) according to sequential 
identity and substrate preference6. Among them, preferential reactivity for α-fructosyl molecules such as F-V 
and F-VH and low reactivity for ε-fructosyl molecule as ε-F-K is a characteristic of group I FPOX. HbA1c is 
generated via α-glycation of N-terminal amino group of Hb β-chain. Therefore, group I FPOX were expected to 
represent favourable templates for creating HbA1cOX. Thus, we performed activity-based screening using a fun-
gal library to obtain a template enzyme, referring to the F-V/ε−F-K ratio as an index. Aspergillus nidulans FPOX 
(AnFPOX-1), which had a remarkably high F-V/ε-F-K ratio, was identified and recombinantly expressed using 
Escherichia coli. Preliminary modification of AnFPOX-1 was performed via cumulative random mutagenesis 
to improve its reactivity for F-VH as the model substrate of HbA1c and thermal stability. AnFPOX-15, which 
featured 11 amino acid replacements in AnFPOX-1 exhibited significant F-VH oxidation activity, whereas reac-
tivity for longer fructosyl peptides such as fructosyl tripeptide (F-3P, Fru-VHL), fructosyl tetrapeptide (F-4P, 
Fru-VHLT) and F-6P was never observed. By contrast, AnFPOX-15 features a robust backbone with high thermal 
Figure 1. The scheme of the HbA1c enzymatic assay and N-terminal six amino acids of the haemoglobin (Hb) 
β-chain and its glycation site. (a) Reaction scheme of the HbA1c enzymatic method. A red arrow indicates the 
current enzymatic method consists of specific two tandem enzymatic reaction, namely, proteolysis of HbA1c 
and the subsequent oxidation of the liberated fructosyl valyl histidine (F-VH) by fructosyl peptide oxidase 
(FPOX). Afterwards, according to the general detection method, the generated hydrogen peroxide (H2O2) is 
then reacted with a chromogen in the presence of peroxidase to produce a dye. The concentration of F-VH can 
be quantitatively determined by measuring the specific absorption of the dye. The amount of F-VH reflects 
that of HbA1c stoichiometrically. A blue arrow indicates the novel enzymatic method employing HbA1c 
direct oxidase (HbA1cOX) to form H2O2. H2O2 can be converted to a signal in the same manner as the current 
method. (b) Left, Hb β-chain structure (PDB id: 2ND2) is shown as a surface model, and the haem prosthetic 
group is shown as an orange stick model. The N-terminal valine, the glycation site of HbA1c, is coloured red. 
The N-terminal six amino acids are shown as a line model and superimposed on the surface model of Hb 
β-chain. Right, magnified structure of the N-terminal six amino acids of the Hb β-chain. The orange pentagon 
at an amino group of the N-terminal valine denotes the fructosyl moiety, suggesting a plausible F-6P structure.
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stability (Supplementary Information). We decided to adopt AnFPOX-15 for further drastic structural modifica-
tion to create HbA1cOX.
To obtain a novel enzyme with beneficial enzymatic characteristics, rational mutagenesis based on the crystal 
structure is an effective approach. At the beginning of our study, the crystal structure of only one fungal FPOX, 
namely AfFAOX-II (FPOX group III), was available14. Low amino acid sequence identity (37%) and sequential 
alignment between AfFAOX-II and AnFPOX-15 (Fig. S1 and Table S3) suggested structural differences in active 
sites and the tunnel shape of active site. Therefore, for detailed and rational design using AnFPOX-15 as a tem-
plate, its crystal structure was essential information. The target sites for mutagenesis were determined based on 
the crystal structure, and F-6P was used as the substrate instead of HbA1c to facilitate screening of the enzymes 
with higher activity than AnFPOX-15.
By combining structure-based site specific mutagenesis and random mutagenesis, we finally generated 
AnFPOX-47 with dramatically improved F-6P reactivity by replacing 10 amino acids in AnFPOX-15. In par-
ticular, replacement of R61 with a smaller amino acid was a key mutation step for obtaining oxidation activity 
for bulky fructosyl substrates. Using AnFPOX-47, we examined direct oxidation of HbA1c using an assay system 
without protease and detected signals with high correlation with the values obtained using conventional HPLC 
method.
In this study, we drastically changed the substrate specificity of FPOX via structure-based site specific 
mutagenesis and random mutagenesis to create a novel HbA1cOX that can recognise the whole HbA1c protein 
as a substrate, thus demonstrating the development of a novel concept of HbA1c measurement, “HbA1c direct 
enzymatic assay”.
Results and Discussion
Crystal structure of AnFPOX-15. Through our screening, we identified wild-type AnFPOX-1 produced 
by A. nidulans. Random mutagenesis was applied to AnFPOX-1 in a stepwise manner to generate AnFPOX-15. 
AnFPOX-15 possessed high substrate specificity for F-VH and high thermal stability (Table S1). However, no 
obtained mutants exhibited reactivity for fructosyl peptides longer than F-VH in the course of AnFPOX-15 gen-
eration via random mutagenesis (Supplementary Information). Therefore, we initially attempted to determine the 
crystal structure of AnFPOX-15 for detailed rational design.
The crystal structure of AnFPOX-15 was resolved using single-wavelength anomalous diffraction (SAD), and 
both of the crystal structure of the ligand-free AnFPOX-15 and that of fructosyl thioacetate (FSA, mimic of fruc-
tosyl glycine, competitive inhibitor of FPOX14) complex (here after described as AnFPOX-15/FSA) were deter-
mined at 2.60 and 1.85 Å resolution, respectively. Table S4 summarises the results of X-ray data collection and 
structure refinement. The refined models comprised 431 residues for a protein molecule in an asymmetric unit, 
although the enzyme consisted of 438 residues. All amino acid residues (P3-R433), except for the N-terminal 
residues (M1 and A2), could be assigned to the 2Fo-Fc map; however, the electron-density map for residues 
S297-I303 and H309-P313 were relatively ambiguous.
The overall structure of AnFPOX-15 consisted of two domains (Fig. 2(a)): an oxidoreductase FAD-binding 
domain with the topology of an incomplete anti-parallel β-barrel (two β-sheets with eight β-strands) and four 
α-helices at one side of the β-barrel; and a catalytic domain with two β-sheets (eight or two β-strands), and 
two long α-helices (helix 2 and 3) that locate at each side of the sheets, and some short helices. The structure of 
AnFPOX-15 resembled the known structures of other FPOX enzymes (Table S3). Recently, the crystal struc-
tures of group I FPOX, namely Eupenicillium terrenum FPOX (EtFPOX)17 and Phaeosphaeria nodorum FPOX 
(PnFPOX)18, were reported. They both shared high amino acid sequence identity with AnFPOX-15 (Fig. S1 and 
Table S3) as well as showed quite low rmsd value compared with AnFPOX-15 (0.80 Å and 1.12 Å, respectively), 
suggesting their structural similarity.
No significant structural difference was observed between the ligand-free AnFPOX-15 and AnFPOX-15/FSA 
(rmsd = 0.46 Å for 429 Cα atoms). No gate-closing structural change was observed upon binding of FSA at the 
active site, which corresponded with the structural characteristics of group I FPOX17. Hereafter, unless otherwise 
indicated, the structural descriptions are provided for the AnFPOX-15/FSA structure.
Interactions between FAD or FSA and AnFPOX-15 are summarised in Fig. 2(b) and Table S5. The flavin ring 
of FAD and thioacetate group of FSA were arranged in a parallel manner, as firstly reported for the FPOX struc-
ture of A. fumigatus FAOX-II (AfFAOX-II)14. The conformations of the amino acid residues surrounding FAD 
in AnFPOX-15 were essentially common to those in other known FPOX. FSA consists of two moieties, namely 
fructosyl and thioacetate moieties. The interactions of the fructosyl moiety of FSA with E282, G376 and R419 
in AnFPOX-15 were common to those of AfFAOX-II, although the residues that interacted with the thioacetate 
moiety of FSA varied, suggesting that the substrate preference of FPOX family enzymes was determined by the 
residues at this site.
Regarding random mutagenesis for AnFPOX-15 generation, introducing the S71Y mutation into AnFPOX-1 
led to significant F-VH oxidation activity (Table S1 in Supplemental Information). Kim et al. reported that G60 of 
PnFPOX is the decisive residue for F-VH oxidation activity19. Seventy-first residue and 59 residue (corresponding 
to G60 of PnFPOX) of AnFPOX-15 were structurally distant, as 71 residue is located in helix 2 and behind loop 
A, whereas 59 residue is located in loop A. They could both contribute to F-VH oxidation activity by affecting the 
flexibility of loop A.
Structure-based mutation design. The gate for the substrate-binding site was formed by loop A (I60-N64) 
and loop B (W407-D425) (Fig. 2(a)). As the structure model (Fig. 3(a)upper) shows, R61 and R63 in loop A and 
R419 in loop B formed a narrow space for the gate. R419 appeared essential for the recognition of fructosyl moiety 
(Fig. 2(b) and Table S5). Whereas, R61 was located near an amino acid residue of the substrate rather than the fruc-
tosyl moiety (Fig. 2(b)). The side-chain of R61 did not form hydrogen bond or salt bridge with FSA; nevertheless, the 
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distance between the Cα atom of R61 and the oxygen atom (OAB) of FSA was close (5.1 Å) (Fig. 2(b)). That suggests 
R61 residue does not participate in substrate binding but obstruct entrance of substrate sterically.
Thus, mutation of R61 to smaller residues was expected to widen the space of the substrate gate and improve 
the affinity between the enzyme and substrates consisting of longer peptides. Based on these observations, we 
selected R61 as the primary candidate to obtain FPOX with reactivity for whole HbA1c. For the modification 
procedure, we employed F-6P, a glycated N-terminal six amino acids of HbA1c, as an index substrate for the 
convenient evaluation instead of HbA1c itself.
The first-generation mutants, in which R61 was replaced with glycine or alanine, displayed significant oxida-
tion activities for F-6P (Fig. 3(c)). To confirm the structural influence of the R61G mutation, the crystal structure 
of AnFPOX-15 R61G was determined. Ligand-free AnFPOX-15 R61G and AnFPOX-15 R61G/FSA structures 
were crystallised under similar condition as those used for AnFPOX-15, and the structures were determined via 
molecular replacement using coordinates of AnFPOX-15 as the initial model. The substrate gate in AnFPOX-15/
R61G was apparently wider than that in the original AnFPOX-15 (Fig. 3(a,b)), indicating that the mutation was 
successfully introduced as designed. No other significant structural differences were found between AnFPOX-15 
and AnFPOX-15 R61G (rmsd = 0.148 Å for 431 Cα atoms). As well as in the case of AnFPOX-15, no signifi-
cant structural difference was observed between the ligand-free AnFPOX-15 R61G and AnFPOX-15 R61G/FSA 
(rmsd = 0.17 Å for 431 Cα atoms).
Site-saturation mutagenesis of R61 revealed that R61S was the best substitution for F-6P oxidation activity 
(Fig. 3(c)), suggesting that reactivity for F-6P could be induced not only by reducing the size of the side-chain on 
Figure 2. Crystal structure of AnFPOX-15. (a) The overall structure of FPOX-15/FSA. Colours denote the 
secondary structure elements (red: α-helices; yellow: β-strands; green; loops and coils). Loop A and B are 
shown in gray. FAD, FSA, sulphate ion and oxidised DTT are shown as ball and stick model in cyan, purple and 
blue respectively. The figures were prepared using cross-eyed stereo diagram. (b) The substrate-binding site of 
FPOX-15/FSA. FSA and the surrounding amino acid residues are shown at cross-eyed stereo diagram. Dashed 
lines indicate hydrogen bonds between FSA and FPOX-15. Oxygen atoms of FSA molecule are labeled with 
OAA-OAJ. FAD is also shown partially.
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at 61 residue but by other factors. AnFPOX-15 R61 mutants including R61G, R61A, R61V and R61S were the first 
AnFPOX mutants with significant F-6P oxidation activities in this study.
Wild-type PnFPOX was reported to have F-6P oxidation activity, although the critical residues in the PnFPOX 
amino acid sequence for this activity were not specified. Alignment analysis revealed that PnFPOX possesses 
a serine at the corresponding site of AnFPOX R61 (Fig. S1), suggesting this serine would contribute to F-6P 
reactivity16.
Structural modification via site specific mutagenesis and random mutagenesis. Using AnFPOX-15 
R61S as a template, the neighbouring L62 and R63, which are both aligned in loop A, were also subjected to 
site-saturation mutagenesis. Consequently, we identified the effective substitutions L62G and R63A. AnFPOX-18 
featuring these mutations exhibited 3.49-fold higher F-6P specific activity (0.401 mU/mg; Table 1).
Next, we attempted the three rounds of random mutagenesis to identify additional effective sites (Fig. S2). 
To evaluate random mutagenesis library, we employed a two-step activity assay. In the first rough selection, F-V 
oxidation activity was assayed, and clones exhibiting higher signals (higher rank 25%) were selected. Then, the 
selected clones were evaluated using F-6P as a substrate, and the clones displaying significant signals were isolated 
and subjected to sequence analysis. The amino acid position of each degenerated mutation was regarded as an 
effective site, and they were optimised via site-saturation mutagenesis.
Figure 3. The structure of the active site gates of AnFPOX-15 and AnFPOX-15 R61G and the mutation effect 
of the R61 residue for F-6P reactivity. (a) Coordination of amino acids around the active site of AnFPOX-15. 
AnFPOX-15/FSA (upper) and AnFPOX-15 R61G/FSA (lower) are shown. The molecule in the right panel is 
rotated 70° from that in the left panel. R61 residue of AnFPOX-15 and G61 residue of AnFPOX-15 R61G are 
coloured red. (b) Focused molecular surface view of the active site gates of AnFPOX-15/FSA and AnFPOX-15 
R61G/FSA. Each 61 residue is shown in red. Coordinated FSA and FAD are shown as stick models in cyan and 
magenta, respectively. (c) Change in F-6P oxidation specific activity by replacing R61 of AnFPOX-15. n.d.: not 
detected.
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The first round focused on the active site, including loop A and helix 3 (F58-G119), using an AnFPOX-
18-expressing plasmid as a template, resulting in the isolation of four effective replacements. Namely, Y71 in 
helix 2 located behind loop A in AnFPOX-15 structure was replaced with serine. M108 and D115, which were 
aligned in helix 3, were replaced with lysine and arginine, respectively. Substitution of L75 with phenylalanine 
also contributed to the elevation of F-6P oxidation activity. AnFPOX-21, which was generated by introducing 
aforementioned mutations into AnFPOX-18, resulted in significant elevation of F-6P oxidation activity (23.0 
mU/mg; Table 1).
Following a second round focused on the M1-G119 region using an AnFPOX-21-expressing plasmid as a 
template, two additional effective mutations were identified: P66H and K108R. The amino acid at 108 residue 
was switched from methionine to lysine in a previous random mutagenesis. Mutations in AnFPOX-21 resulted 
in the generation of AnFPOX-36 mutant with F-6P oxidation activity of 43.0 mU/mg. In the third round using 
an AnFPOX-36-expressing plasmid as a template, we selected a region that was unlikely to directly participate 
in substrate-binding (N330-E391). Consequently, two additional mutations, F342V and A355S, were identified. 
Concerning the two identified mutations, F342V was located away from the active site, and A355S was located 
on the opposite edge of the active site of helix 3. AnFPOX-47 featuring these two mutations exhibited the highest 
F-6P oxidation activity (82.4 mU/mg; Table 1).
The F-6P oxidation activities of AnFPOX mutants were dramatically improved via three rounds of random 
mutagenesis, and AnFPOX-47 displayed 717-fold higher activity than AnFPOX-15 R61S mutant (Table 1).
Enzymatic characterisation of the generated AnFPOX mutant. AnFPOX-47 was evaluated for sub-
strate specificity, especially for fructosyl peptides. AnFPOX-47 exhibited the highest reactivity for F-6P, followed 
by F-3P and F-4P (Fig. 4(a)). AnFPOX-15 R61S demonstrated substrate preference for shorter fructosyl peptide 
as F-3P, suggesting that the entrance of a longer substrate was structurally hindered. On the contrary, the sub-
sequently generated mutants clearly exhibited greater preference for F-6P (Fig. 4(a)). The result of the oxidation 
activity assay of AnFPOX-47 using the alanine replacing analogues of F-6P indicated that the specific recognition 
for both the L3 and E6 residues of F-6P contributes to high F-6P reactivity of AnFPOX-47 (Fig. 4(b)). No signal 
was observed in the case of using fructosyl hexapeptide of the glycated Hb α-chain (F-6P[α], Fru-VLSPAD), indi-
cating extremely high specificity for the sequence and structure of F-6P (Fru-VHLTPE), and a low risk of reacting 
with non-HbA1c glycated Hb via AnFPOX-47 (Fig. 4(c)).
In the application of modified enzymes as diagnostic reagents, their thermal stability is also a critical factor 
because the stability directly reflects the longevity of the reagent. Following the modification, the thermal stability 
of AnFPOX-47 decreased from AnFPOX-15, but retained a relatively high level as compared with the wild-type 
AnFPOX-1 (Fig. S3). The high structural robustness of AnFPOX-15 might contribute greatly to the retention of 
high stability even after several rounds of mutagenesis.
Structural assessments of AnFPOX-15 and AnFPOX-21 mutants. To assess structural differ-
ences between AnFPOX-15 and AnFPOX-21, for which the largest improvement of F-6P oxidation activity was 
observed, the obtained X-ray crystal data were structurally analysed.
AnFPOX-21/FSA was crystallised and the structure was determined via molecular replacement. The crys-
tal belonged to P65, and it contained two enzymes arranged in an asymmetric unit. Although all amino acid 
residues from P3 to N434 were identified in one molecule, but S61, G62, and A63 in the other molecule were 
omitted from the final coordinate file because of the poor electron-density map. No significant structural differ-
ence was noted between AnFPOX-15 and AnFPOX-21 (rmsd = 0.436 Å and 0.441 Å for 431 and 427 Cα atoms, 
respectively), excluding for the structures in mutated residues, suggesting conservation of the elemental archi-
tecture of AnFPOX even after gaining significant F-6P oxidation activity by introducing seven mutations. With 
respect to AnFPOX-21 the B-factor values of the Cα atom of loop A (S61-N64) was significantly high even in 
coordinate-determined chain (S61, 94.22 Å3; G62, 84.36 Å3; A63, 94.43 Å3), suggesting structure flexibility of loop 
A because of the mutations. The flexibility of the main-chain in this region was not observed in AnFPOX-15 and 
AnFPOX-15 R61G (Fig. 5(a)lower).
As S61, G62 and A63 have a smaller side-chain size in AnFPOX-21 than original AnFPOX-15, the mutations 




AnFPOX-15 none n.d. —
AnFPOX-15 R61G R61G (1) 0.102 ± 0.002 —
AnFPOX-15 R61S R61S (1) 0.115 ± 0.001 1.00
AnFPOX-18 R61S/L62G/R63A (3) 0.401 ± 0.016 3.49
AnFPOX-21 R61S/L62G/R63A/Y71S/L75F/M108K/D115R (7) 23.0 ± 0.320 200
AnFPOX-36 R61S/L62G/R63A/Y71S/L75F/D115R/K108R/P66H (8) 43.0 ± 1.09 374
AnFPOX-47 R61S/L62G/R63A/P66H/Y71S/L75F/M108R/D115R/F342V/A355S (10) 82.4 ± 2.53 717
Table 1. Summary of AnFPOX mutants generated in this study. Mutations given in bold indicate additional 
mutations introduced in the generation. Specific activity data are presented as the mean ± SD (n = 3). *The fold 
change of F-6P specific activity compared with the value for AnFPOX-15 R61S. The value for AnFPOX-15 R61S 
was regarded as 1.00. n.d.: not detected.
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flexibility resulting from these mutations are believed to contribute to the observed increased F-6P reactivity 
(Fig. 5(a)).
In addition, F-6P possesses histidine residue (H2) which could carry positive charge under physiological con-
dition. Therefore, there is a possibility that cancellation of charge repulsion between R61 and R63 with H2 of F-6P 
via the mutations facilitates entrance of F-6P into catalytic site of AnFPOX mutants.
PnFPOX and some of the derivatives were reported to have F-6P oxidation activity16. In that report, exchang-
ing loop 1 structure (corresponding to loop A of AnFPOX-15) of CoFPOX (non-F-6P reactive FPOX) with that 
of PnFPOX (F-6P reactive FPOX) resulted in generation of CoFPOX chimera enzyme with F-6P reactivity16. 
This result also corresponds to our result that modification of loop A of AnFPOX was elementally important for 
acquiring F-6P reactivity.
The four mutations identified on the first round of random mutagenesis, namely Y71S, L75F, M108K and 
D115R, significantly contribute to the improvement of F-6P oxidation activity (57-fold improvement compared 
with that of AnFPOX-18). The contribution of these four mutations could be divided into two aspects: i) indirect 
effects on the flexibility of loop A (Y71S and L75F) and ii) conversion of the electric charges in helix 3 (M108K 
and D115R).
Mutation of Y71 in the AnFPOX-21 mutant to serine reduced the size of the side-chain. Considering the 
entrance of bulky substrates into the active site, loop A in particular would be pushed backwards to accommodate 
the substrate. The Y71S mutation could permit the acceptance of such a structural change by alleviating structural 
interference with the facing I60 residue (Fig. 5(b)). Our study revealed that substitution of S71 in AnFPOX-1 with 
tyrosine conferred F-VH reactivity (Table S1). The obtained mutation after the AnFPOX-15 mutagenesis study 
demonstrated that the ancestral amino acid (serine) was effective for F-6P reactivity, implying that the beneficial 
structure for F-VH oxidation activity is not necessarily in concordance with that for F-6P oxidation activity.
Figure 4. Substrate specificity of the generated AnFPOX mutants. (a) Specific activity ratio% of AnFPOX 
mutants for fructosyl tripeptide (F-3P), fructosyl tetrapeptide (F-4P) and F-6P, each specific activity for F-3P 
was regarded as 100%. (b) Specific activity of AnFPOX-47 for F-6P and its analogues. Data are mean ± SD 
(n = 3). F-6P analogues share the common amino acid sequence excluding the replacement of one amino acid 
with alanine. (c) Comparison of specific activity for F-6P and F-6P[α]. Data are mean ± SD (n = 3). F-6P[α] is a 
fructosyl hexapeptide of the glycated Hb α-chain, featuring the amino acid sequence of VLSPAD with glycation 
at an amino group of the N-terminal valine. F-6P[α] is an interfering substance in the HbA1c measurement. 
n.d.: not detected.
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Figure 5. Structural change by mutations introduced into AnFPOX. (a) Upper: Structural difference of loop 
A of AnFPOX-15/FSA and AnFPOX-21/FSA shown as a cartoon model with side-chain as a stick model. 
Lower: each loop A is shown as setting by B-factor putty on PyMOL programme. Warm colour shows high B-
factor, and the reduced B-factor following in the order of red, orange, yellow, sky blue then blue. (b) Structural 
difference of 71 residue in helix 2 was compared between AnFPOX-15/FSA and AnFPOX-21/FSA. Y71 
residue was replaced with serine in AnFPOX-21. (c) Structural difference of 75 residue in helix 2 was shown 
as a cartoon model to compare 75 residue between AnFPOX-15/FSA and AnFPOX-21/FSA. L75 residue was 
replaced with phenylalanine in AnFPOX-21. (d) The upper panel shows structural difference of helix 3 between 
AnFPOX-15/FSA and AnFPOX-21/FSA. Each structure is shown as a cartoon model. The side-chain of the 
featuring residues is shown as a stick model. Magenta indicates innate basic residues on AnFPOX-15, blue 
indicates acidic residues and red indicates basic residues newly introduced in the generation of AnFPOX-21. 
Lower panel, the left figure shows the active site of AnFPOX-21/FSA. Dotted arrows show the distance from 
the sulphur atom of FSA to the α-carbon of each K108 and R115. Right figure shows rough structural model 
of F-6P. An orange pentagon indicates a fructosyl moiety. The distances were measured using the crystal 
structure of the haemoglobin β-chain (PDB id: 2DN2) using the PyMOL programme. The distance of approx. 
16 Å is a length from nitrogen of N-terminal valine to α-carbon of P5, and distance of approx. 3.8 Å is a length 
from α-carbon of P5 to that of E6. The side-chain length of R115 is approximately 7 Å, and that of E6 of F-6P 
is approximately 4.7 Å. When F-6P is coordinated onto FAD of AnFPOX-21, E6 of F-6P is located around the 
active site gate, enabling the formation of electrostatic interactions between them. (e) The active site gates of 
AnFPOX-15/FSA and AnFPOX-21/FSA are shown in surface model. Coordinated FSA and FAD are shown as 
cyan and magenta, respectively.
www.nature.com/scientificreports/
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L75F, which is located in helix 2 and behind loop A, also contributes to the enhancement of F-6P oxidation 
activity, even though no significant structural change was induced. The L75F mutation probably had a fine-tuning 
effect on the interaction between loop A and helix 2 (Fig. 5(c)).
M108K and D115R, which are located in helix 3, resulted in alignment of six positive-charged amino acids in 
a condensed manner (Fig. 5(d)upper). When F-6P enters the active site and its fructosyl moiety is coordinated 
on FAD, E6 (sixth glutamic acid of F-6P) is estimated to be placed near the gate of the active site (Fig. 5(d)lower). 
The result of the activity assay using the F-6P analogues suggests the importance of E6; therefore, electrostatic 
interactions between E6 and the aligned positive-charged amino acids in helix 3 would contribute to the stabili-
sation of F-6P binding.
K104 and K105 were previously introduced in the generation of AnFPOX-15 from glutamic acid and glycine, 
respectively. These basic amino acids could also support the electrostatic interaction with the E6 of F-6P; hence, 
using AnFPOX-15 as a modification template may have proven advantageous for our purpose (Fig. 5(d)upper).
An activity assay using F-6P analogues also suggested the importance of L3 of F-6P (Fig. 4(b)). Considering 
the distance from the fructosyl moiety of F-6P, the hydrophobic side-chain of A63, switched from arginine resi-
dues, would play a role in recognition.
The surface model of the AnFPOX-21/FSA structure illustrated the opened active site gate even after FSA 
binding (Fig. 5(e)). No gate-closing structural change upon substrate (inhibitor) binding is a specific character-
istic of group I FPOX17, which is also observed for AnFPOX-15/FSA and AnFPOX-15 R61G/FSA structures. 
In addition, the active site gate of AnFPOX-21 is apparently wider than that of AnFPOX-15, and the thioac-
etate moiety of FSA coordinated on AnFPOX-21 was observable from outside the molecule (Fig. 5(e)). This 
wide-opened gate of AnFPOX-21 is expected to be advantageous for F-6P accessibility and reactivity because the 
larger space should permit longer peptides to be accommodated.
As the crystal structures of mutants generated after AnFPOX-21 have not been solved, the effects of replace-
ment identified in the second and third rounds of random mutagenesis were considered using the structural 
models generated using the PyMOL programme based on the AnFPOX-21/FSA structure.
In the second round of random mutagenesis, two effective replacements were identified, namely P66H and 
K108R, although their contribution to F-6P oxidation activity was relatively modest (1.87-fold increase versus 
AnFPOX-21).
P66 residue is placed on the connexion of loop A and helix 2 (Fig. S4). As shown by the increased B-factor 
of loop A in AnFPOX-21 (Fig. 5(a)), high flexibility of loopA was expected to be beneficial for F-6P reactivity. 
Judging from the structural model of the P66H mutation generated by the PyMOL programme, the P66H muta-
tion is also expected to effect on flexibility of loop A.
Replacement of K108 with arginine results in elongation of the positive-charged side-chain, from approxi-
mately 5.4 Å of that of lysine to approximately 7 Å of that of arginine. The elongated side-chain could widen the 
supporting range of electrostatic interaction with the E6 of F-6P.
In the third round of random mutagenesis, F342V and A355S were identified as mutations that elevate F-6P 
oxidation activity (1.92-fold growth compared with AnFPOX-36), although their contributions are still unclear.
F342 in AnFPOX-21 is located completely away from the active site (Fig. S5(a)). In the mutation study, 
replacement of F342 in AnFPOX-36 with valine resulted in slight elevation of F-6P reactivity and reduction of 
F-V reactivity. Conversely, replacement of F342 with glycine reduced both F-V and F-6P reactivities (Fig. S5(b)). 
Shimasaki et al. reported that N56 of PnFPOX (corresponding to conserved N55 residue of AnFPOX), which is 
located on the re-face side of the isoalloxasine ring of FAD of PnFPOX, similarly as F342 of AnFPOX, plays an 
important role in O2 invasion, and it is indispensable for the oxidase reaction18. Taken together, the F342 muta-
tion may also influence the oxidative half-reaction of FPOX.
A355S is positioned on the opposite side of the active cleft from helix 3 (Fig. S6). Although the role of this site 
remains unclear, S355 is believed to facilitate the entrance of F-6P into the active site.
Direct oxidation of HbA1c by AnFPOX mutants. In the assay using Hb as a sample, strong absorption 
of Hb interfered with detection of the colourimetric reaction signals. Hence, to evaluate direct oxidation activity 
for glycated Hb, we prepared ApoHb from human Hb, from which the haem prosthetic group was removed, for 
convenient evaluation. Following the method of preparing Apo myoglobin20, ApoHb was successfully prepared as 
indicated by the presence of two major bands corresponding to the α- and β-chains of Hb-protein on SDS-PAGE 
(Fig. S7).
Using ApoHb as a substrate, we evaluated the direct oxidation activity of each of the generated mutants. As 
Fig. 6(a)upper shows, significant signals were detected for AnFPOX-21 and the later mutants, and the signal 
intensities were apparently correlated with the F-6P specific activity of each mutant (Fig. 6(a)lower).
To confirm further whether the detected signals actually resulted from the enzymatic reaction of FPOX, the 
effect of FSA (a competitive inhibitor of FPOX) on oxidation activity was evaluated using AnFPOX-47. The sig-
nal for the ApoHb oxidation activity and that for F-6P oxidation activity were clearly inhibited by FSA in a 
concentration-dependent manner (Fig. 6(b)). Therefore, the detected oxidation activity was enzymatically cata-
lysed by AnFPOX-47.
Finally, we investigated the HbA1c direct oxidation activity of AnFPOX-47 using washed human erythrocytes 
as a sample to evaluate the practical potential for its diagnostic use. As a significant signals were detected in this 
assay system without a protease pre-treatment step, it is strongly implied that the signals were derived from direct 
oxidation of the whole HbA1c protein. Furthermore, signals measured by AnFPOX-47 and the concentrations of 
HbA1c determined by HPLC method exhibited a high correlation (Fig. 6(c)).
The concentration of HbA1c in each of the samples was calculated based on the calibration curve prepared 
using washed erythrocyte samples, which included a known concentration of HbA1c. HbA1c% (abundance of 
HbA1c molecule over total Hb) for each sample was calculated using the measured and calculated concentration 
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of HbA1c and that of Hb determined by Hb-SLS kit (Wako, Japan) of which principle was described by Oshiro et 
al.21.The resulting HbA1c% values of the measured samples actually exhibited a high correlation with the values 
determined by HPLC (Fig. 6(d)), suggesting that AnFPOX-47 could work as the HbA1cOX.
Figure 6. Evaluation of the HbA1c direct oxidation activity of the generated mutants. (a) Upper panel, the 
detection of ApoHb oxidation activity using each of the generated AnFPOX mutants (final concentration of 
230 μg/mL) and ApoHb (final concentration of 1.36 mg/mL, including 7.1% HbA1c). A signal was calculated 
from the change in absorbance during incubation at 37 °C for 1 h by subtracting absorbance change in reagent 
without enzymes. Data are presented as the mean ± SD (n = 3). n.d.: not detected. Lower panel, correlation 
between the reaction signal intensity using ApoHb (final concentration of 1.36 mg/mL, including 7.1% HbA1c) 
as a substrate and the F-6P specific activity (mU/mg) of each of the mutants. Data are the mean of triplicate 
measurement. (b) Inhibitor (FSA) susceptibility assay of AnFPOX-47 using F-6P (final concentration of 
0.1 mM) and ApoHb (final concentration of 1.36 mg/mL, including 7.1% HbA1c). AnFPOX-47 was used at 
final concentrations of 2.3 and 217 μg/mL for F-6P and ApoHb, respectively. FSA was added and mixed prior 
to substrate addition. Data are presented as the mean ± SD (n = 3). (c) Correlation between the signals (ΔAbs) 
obtained via the reaction of AnFPOX-47 with concentration of HbA1c included in Hb samples. Data are 
presented as the mean ± SD (n = 4). The concentrations of HbA1c was calculated from HbA1c% determined by 
HPLC and the total Hb concentration determined using Hb-SLS method21. AnFPOX-47 (final concentration of 
2.6 mg/mL) was subjected to reaction. The signal (ΔAbs.) was calculated from the change in absorbance during 
incubation for 1 h at 37 °C. (d) Correlation between the HPLC method and our developed assay system using 
AnFPOX-47. HbA1c% was calculated from the average of measured value obtained with AnFPOX-47 based on 
a calibration curve prepared with two independently measured Hb samples (HbA1c%: 6.7 and 12.3).
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Conclusion
In this study, we aimed to create HbA1cOX through structural modification of the partially modified fungal 
FPOX, AnFPOX-15. The crystal structure of AnFPOX-15 illustrated that R61 apparently obstructs the entrance of 
bulky substrates such as F-6P into the active site. From these observations, the generated R61G mutant acquired 
significant oxidation activity for F-6P, and the wider space of substrate gate in R61G mutant was confirmed via 
its crystal structure.
Further mutagenesis using a combination of structure-based site specific mutagenesis and random mutagen-
esis yielded AnFPOX-47 with most highly elevated F-6P oxidation activity. Biochemical characterisation using 
erythrocyte samples demonstrated that AnFPOX-47 is a novel HbA1cOX.
From the perspective of protein engineering, we succeeded in drastically converting the substrate specificity 
from fructosyl peptides to the whole HbA1c protein, which could lead to the development of more convenient 
and high throughput in vitro diagnostics without involving any protease treatment step.
To establish the actual in vitro diagnostics for HbA1c using direct enzymatic oxidation system, further optimi-
sation of the assay conditions is indispensable. The development of an “HbA1c direct enzymatic assay” is ongoing.
Method
Enzyme expression and purification. Escherichia coli DH5α harbouring the pTrc-AnFPOX-15 vector was 
developed as described in the Supplementary Information. The strain was cultured at 30 °C in Luria-Bertani (LB) 
medium (50 mg/L Amp.) with shaking. For the selenomethionine-derivative of AnFPOX-15, E. coli B834 (DE3) 
harbouring the pTrc-AnFPOX-15 vector was cultured in minimal medium including 25 μg/mL selenomethionine. 
Protein expression was induced by adding isopropyl-β-D-thiogalactopyranoside (final concentration, 0.1 mM), 
when the turbidity reached approximately 0.5 at 600 nm, followed by continued culture with shaking 16 °C for 44 h.
The recombinant AnFPOX was purified from the cultured cells as described in the Supplementary 
Information. In brief, ammonium sulphate precipitation and the subsequent two steps of column chromatogra-
phy were employed. Purity was confirmed by SDS-PAGE. All AnFPOX mutants could be purified via the same 
procedure (Fig. S8). Protein contents were determined by measuring absorbance at 280 nm and assuming that 
E280 = 1.54 (AnFPOX-15) corresponded to 1 mg/mL22. The contents of other mutants were also determined in the 
same manner using their E280 values.
Activity assay of AnFPOX mutants. Fructosyl substrates and the inhibitor (FSA) were synthesised and 
purchased from Peptide Institute, Inc. (Osaka, Japan)
The activity assay was performed as follows: First, 190 μL of the mixture, containing 10 mM potassium phos-
phate buffer (pH7.0), 3.5 U/L horseradish peroxidase, 0.5 mM 4-aminoantipyrine, and 0.5 mM N-ethyl-N-
(2-hydroxy-3-sulfopropyl)-3-methylaniline, was mixed with 20 μL of 1 mM F-6P, and 10 μL of samples on 
multi-well plate. After incubation at 30 °C, the change of the absorbance at 550 and 690 nm (reference) was meas-
ured using infinite F200 (Tecan, Switzerland). Activity was calculated as the change in absorbance based on the 
calibration curve prepared on the absorbance derived from known concentrations of H2O2. One unit of activity 
was defined as the quantity of enzyme that could catalyse the formation of 1 μmol of H2O2 per minute. Specific 
activity was defined as the activity catalysed by 1 mg of FPOX. For high-sensitivity measurement, 30 μM DA-67 
(Wako, Japan) was employed and absorbance at 660 and 750 nm (reference) was used for the measurement.
For evaluation on screening, cell-free extracts of clones were prepared on multi-well plates as described in 
Supplementary Information.
Crystallisation and X-ray diffraction. For crystallisation of AnFPOX-15, purified AnFPOX-15 
selenomethionine-derivative was concentrated to 6.5 mg/mL using the Centriprep (Merck Millipore, USA). In 
the case of inhibitor complex, fructosyl thioacetate (FSA) was added at 10 mM concentration.
The crystallisation conditions were initially screened by sparse-matrix screening in a 96-well Intelli-plate (Art 
Robbins instruments) by commercial crystallisation kits from Hampton Research (Crystal Screen 1 and 2), Jena 
Science (JBScreen Classic 1–10) and Emerald Bio Systems (Wizard Classic Crystallization Screen 1 and 2), at 
20 °C using the sitting-drop vapour-diffusion method. The crystals of AnFPOX-15 selenomethionine-derivative 
and the FSA complex were obtained after incubation for 3–7 days, in Wizard Classic 1 No. 33 (2.0 M ammonium 
sulphate, 0.2 M lithium sulphate, and 0.1 M N-cyclohexyl-3-aminopropanesulfonic acid (CAPS) buffer, pH 10.5. 
Trigonal crystals were generated under the optimised condition of 1.75 M ammonium sulphate, 0.2 M lithium 
sulphate, and 0.08 M CAPS buffer (pH 10.4). The crystals of AnFPOX-15 R61G and AnFPOX-15 R61G/FSA were 
obtained in the similar manner for AnFPOX-15.
For the AnFPOX-21/FSA, purified AnFPOX-21 was concentrated to 20 mg/mL, to which 10 mM of FSA was 
added. The crystallisation conditions were screened following the method as described above, using the sitting-drop 
vapour-diffusion method. Crystal of AnFPOX-21/FSA was obtained after incubation for 2 weeks at 20 °C, in PGA 
Screen-CF-D9 solution containing 20% (w/v) PEG 3350, 0.1 M 2-morpholinoethanesulfonic acid (MES; pH6.5) and 
5% (w/v) poly-γ-glutamic acid (molecular mass: 200–400 kDa) in The PGA Screen Kit (Molecular Dimensions, USA).
For cryoprotection, a crystal was soaked in the reservoir solution containing 20% glycerol and picked up 
with a mounted nylon loop (Hampton Research). The crystal was then placed directly into a nitrogen gas stream 
at −173 °C. X-ray diffraction images were acquired at −173 °C under a nitrogen gas stream with a Quantum 
210 CCD Detector (ADSC) and synchrotron radiation (λ = 0.97980 Å for ligand-free AnFPOX-15 or 1.00000 Å 
for other crystals) at the BL-38B1 station of SPring-8 (Hyogo, Japan). In the case of the AnFPOX-15/FSA, data 
were obtained using the MAR225HE CCD detector (Rayonix) at BL-44XU station of SPring-8. X-ray diffraction 
images of AnFPOX-21/FSA were acquired at −173 °C under a nitrogen gas stream with the Dectris Pilatus3 S 
6 M Detector and synchrotron radiation (λ = 0.98000 Å) at the BL17A Station of Photon Factory (Ibaraki, Japan).
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Structure determination and refinement. The diffraction data sets were processed using the HKL2000 
programme package (HKL Research, Inc., USA). The crystal structure of AnFPOX-15 was resolved using SAD 
with the selenomethionine-derivative crystal. Phase determination and initial model building for the AnFPOX-15 
derivative were performed using the AutoSol wizard23 supplemented with the PHENIX graphical interface24. 
The winCOOT programme (http://bernhardcl.github.io/coot/) was used to manually modify the initial model. 
Initial rigid body refinement and several rounds of restrained refinement against the dataset were conducted 
using the phenix.refine programme with the Translation/Libration/Screw (TLS) refinement. Water molecules 
were automatically incorporated where the Fo-Fc and 2Fo-Fc electron density map showed a density of > 3.0 
and 1.3 σ, respectively. Figures for ribbon plots were prepared using the PyMOL programme (Schrödinger, LLC, 
New York, USA). The crystal structures of the AnFPOX-15/FSA, AnFPOX-15 R61G, AnFPOX-15 R61G/FSA 
and AnFPOX-21/FSA were also determined through the molecular replacement method using the Phaser pro-
gramme25 in the PHENIX graphical interface using the structure of ligand-free AnFPOX-15 as a search model. 
Refined structures were validated using the MolProbity programme26 in the PHENIX graphical interface. The 
coordinates used in this report were obtained from the Protein Data Bank (PDB), Research Collaboratory 
for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/). RMS deviation 
between the two models was calculated using the SSM superpose function in the winCOOT programme.
Site specific mutagenesis and site-saturation mutagenesis. Site specific mutagenesis was employed 
using pTrc-AnFPOX plasmid as a template following the methods described in the QuikChange Site-directed 
Mutagenesis kit (Stratagene, CA, USA), except that KOD-Plus-polymerase was used. Oligonucleotides were syn-
thesised at the Hokkaido System Science (Japan). Oligonucleotides sequences used in this study were summarised 
in Table S6. Introduced mutations were confirmed by DNA sequencing by ABI3700 sequencer with two primers, 
pTrc-F and pTrc-R. E. coli DH5α cell was transformed using generated plasmid.
Site-saturation mutagenesis was performed following the same method as in site specific mutagenesis, except 
for using primer pairs containing NNS (N: A, T, G, or C, S: G or C) on the target site. Two hundreds of colonies 
were evaluated to isolate favourable clones for subsequent analysis.
Random mutagenesis. Random mutagenesis was performed via error-prone PCR following the method 
reported by Kawate et al.27 using rTaq polymerase (Toyobo, Japan). The reaction mixture was prepared following 
manufacture’s protocol except for using dNTP mixture consisted of 0.2 mM dATP, 1 mM dTTP, 0.1 mM dGTP 
and 1 mM dCTP. Ten nano gram of plasmid DNA was added as a template. PCR condition was as follows: 94 °C, 
2 min, followed by 45 cycles of 94 °C, 30 sec, 50 °C, 30 sec, and 72 °C, 30 sec, then 72 °C, 1 min.
Amplified PCR product was ligated into the template plasmid and introduced into E. coli DH5α. The colonies 
grown on LB agar medium (50 mg/L Amp.) were evaluated as a library. In brief, the colonies were picked and their 
cell free extract was prepared on multi-well plate. In a first round of evaluation, 25% of the clones that exhibited 
higher signals using F-V (final concentration of 0.09 mM) were selected. In the subsequent round, the selected 
colonies were then evaluated using F-6P (final concentration of 0.03 mM). The clones that exhibited higher signal 
were selected. Approximately 5,000 clones were evaluated on a single round of random mutagenesis.
HbA1cOX activity assay. Human red blood cell specimens with determined HbA1c% values were pur-
chased from Discovery Life Sciences (CA, USA). Their HbA1c% were determined via the conventional HPLC 
(Variant II Turbo Haemoglobin Testing System, Bio-Rad, CA, USA).
ApoHb was prepared from human red blood cell specimens following the method described by Harrison 
et al.20. The obtained ApoHb was dissolved in 5% of Anhitol 20 N solution (lauryldimethylamine oxide; Kao 
Chemical, Japan).
Concerning HbA1c direct oxidation assay for the ApoHb (7.1% HbA1c) or intact HbA1c, the same assay system 
used for F-6P was employed. Prior to the reaction, red blood cell specimens were haemolysed by 5% Anhitol 20 N 
solution and incubated at 37 °C for 15 min. The reaction signals were defined as the change in absorbance during 
incubation at 37 °C for 1 h. The Hb concentrations of haemolysed samples were determined via Hb-SLS kit21 (Wako).
Accession codes. The atomic coordinates and structure factors of AnFPOX-15 selenomethionine-derivative, 
AnFPOX-15 selenomethionine-derivative FSA complex, AnFPOX-15 R61G, AnFPOX-15 R61G/FSA and 
AnFPOX-21/FSA have been deposited in the Protein Data Bank with the accession id of 6A6R, 6A6S, 6A6T, 
6A6U and 6A6V, respectively.
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